|
SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes |
Jun 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM) |
Apr 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. |
Mar 2019 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Silver lining: reduced relapse with chronic GVHD after transplant for MDS |
Oct 2020 |
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Graft Versus Host Disease (GVHD), Myelodysplastic Syndromes (MDS) |
|
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years |
Oct 2019 |
Blood Advances |
Aplastic Anemia |
|
Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia |
Apr 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes |
Dec 2020 |
Hematology/oncology and stem cell therapy |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
T cell dysfunctions in myelodysplastic syndromes |
Jan 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Targeting the Microenvironment in MDS: The Final Frontier |
Jul 2020 |
Frontiers in Pharmacology |
Myelodysplastic Syndromes (MDS) |
|
Targeting TP53 Mutations in Myelodysplastic Syndromes |
Apr 2020 |
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS) |
